ホーム 計算ツール
代理店ログイン

VEGFR

VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. Also, they may be membrane-bound (mbVEGFR) or soluble (sVEGFR), depending on alternative splicing.
Cat. No. 製品名 CAS No. Purity Chemical Structure
T6517 Golvatinib 928037-13-2 98%
Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor ...
T4554 AG 1406 71308-34-4 98%
AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2.
T6057 URMC-099 1229582-33-5 98%
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM)...
T0093 Sorafenib tosylate 475207-59-1 98%
Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).
T2056 VEGFR-2-IN-5 1430089-64-7 98%
VEGFR-2-IN-5 (UNC0064-12) is a patent compound in WO2013055780A1, multikinase inhibitor and has a -NH2 terminal linker for further synthesis.
T2288 Motesanib 453562-69-1 98%
Motesanib (AMG 706) is an orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits...
T1895 SKLB 610 1125780-41-7 98%
SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2, and PDGFR at a rate of 97%, 65%, and 55%, respectively, a...
T14072 A-443654 552325-16-3 98%
A-443654 is a pan-Akt inhibitor. A-443654 has equal potency against Akt1, Akt2, or Akt3 within cells (Ki=160 pM).
T21593 AAL-993 269390-77-4 98%
AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively. AAL993 has a weak inhibitory effect on oth...
T4318 EOC317 939805-30-8 98%
EOC317 (ACTB-1003) is an oral kinase inhibitor (IC50: 6/2/4 nM, for FGFR1/VEGFR2/Tie-2).
T5171 Treprostinil Sodium 289480-64-4 98%
Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).
T9928 Ranibizumab 347396-82-1 98%
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and...
T9904 Bevacizumab 216974-75-3 98%
Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.
T2656 Fruquintinib 1194506-26-7 98%
Fruquintinib (HMPL-013) is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic...
T10123 VEGFR-2-IN-9 408502-06-7 98%
VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer.
T4288 HVEGF-IN-1 1637443-98-1 98%
hVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity.
T4026 SU5408 15966-93-5 98%
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent, cell-permeable inhibitor of the VEGFR2 kinase.
T76866 Icrucumab 1024603-92-6 98%
Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.Icrucumab has antitumor activity.Icrucumab ...
T76756 Parsatuzumab 1312797-14-0 98%
Parsatuzumab (RG 7414) is a humanized monoclonal antibody targeting EGFL7, which is also used as an immunomodulator.Parsatuzumab selectively inhibits the interac...
T75163 GW297361 388627-21-2 98%
GW297361 is a potent inhibitor of the cell cycle protein-dependent kinase Cdk1 and also inhibits the Pho85 signaling pathway.The IC50s of GW297361 on yeast Cdk1 ...
Golvatinib
T6517
Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor ...
AG 1406
T4554
AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2.
URMC-099
T6057
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM)...
Sorafenib tosylate
T0093
Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).
VEGFR-2-IN-5
T2056
VEGFR-2-IN-5 (UNC0064-12) is a patent compound in WO2013055780A1, multikinase inhibitor and has a -NH2 terminal linker for further synthesis.
Motesanib
T2288
Motesanib (AMG 706) is an orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits...
SKLB 610
T1895
SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2, and PDGFR at a rate of 97%, 65%, and 55%, respectively, a...
A-443654
T14072
A-443654 is a pan-Akt inhibitor. A-443654 has equal potency against Akt1, Akt2, or Akt3 within cells (Ki=160 pM).
AAL-993
T21593
AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively. AAL993 has a weak inhibitory effect on oth...
EOC317
T4318
EOC317 (ACTB-1003) is an oral kinase inhibitor (IC50: 6/2/4 nM, for FGFR1/VEGFR2/Tie-2).
Treprostinil Sodium
T5171
Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).
Ranibizumab
T9928
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and...
Bevacizumab
T9904
Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.
Fruquintinib
T2656
Fruquintinib (HMPL-013) is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic...
VEGFR-2-IN-9
T10123
VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer.
hVEGF-IN-1
T4288
hVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity.
SU5408
T4026
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent, cell-permeable inhibitor of the VEGFR2 kinase.
Icrucumab
T76866
Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.Icrucumab has antitumor activity.Icrucumab ...
Parsatuzumab
T76756
Parsatuzumab (RG 7414) is a humanized monoclonal antibody targeting EGFL7, which is also used as an immunomodulator.Parsatuzumab selectively inhibits the interac...
GW297361
T75163
GW297361 is a potent inhibitor of the cell cycle protein-dependent kinase Cdk1 and also inhibits the Pho85 signaling pathway.The IC50s of GW297361 on yeast Cdk1 ...
1 2 3 4 5 6 7 8 9 10 11 12